{"ticker": {"uuid": "ae9d8302-e8d3-4a23-9dc7-58eb5854397a", "symbol": "VYNE", "name": "Vyne Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "VYNE Therapeutics Inc. (VYNE) reports 13.8% stake by Zhang Xiaofan", "summary": "Zhang Xiaofan has reported a 13.8% beneficial ownership stake in VYNE Therapeutics Inc., holding 4,595,118 shares of common stock. This SCHEDULE 13G/A filing indicates that Zhang Xiaofan has sole voting and dispositive power over these shares. The filing lists Zhang Xiaofan's bus", "url": "https://www.stocktitan.net/sec-filings/VYNE/schedule-13g-a-vyne-therapeutics-inc-amended-passive-investment-discl-eeb0bd4053fe.html", "source_name": "Stock Titan", "published_at": "2026-07-14T13:39:35", "published_display": "14 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (NASDAQ: VYNE) shares Yarrow transaction deck", "summary": "VYNE Therapeutics Inc. (NASDAQ: VYNE) reported that Yarrow Bioscience, Inc. has published an investor presentation for investor relations, dated July 14, 2026. This presentation has been made available on VYNE's investor website and filed as Exhibit 99.1. It is clarified that thi", "url": "https://www.stocktitan.net/sec-filings/VYNE/425-vyne-therapeutics-inc-business-combination-communication-c60b38a0f1da.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:39:35", "published_display": "14 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (NASDAQ: VYNE) outlines Yarrow merger, dividend terms", "summary": "VYNE Therapeutics has detailed its proposed reverse merger with Yarrow Bioscience, where the combined company will trade as YARW on Nasdaq around July 24, 2026. Yarrow, founded in 2025, is developing YB-101, an anti-TSHR antibody for Graves\u2019 disease and thyroid eye disease, with ", "url": "https://www.stocktitan.net/sec-filings/VYNE/8-k-vyne-therapeutics-inc-reports-material-event-d25f763da3f2.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:39:35", "published_display": "14 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "VYNE Therapeutics (VYNE) Announces Special Dividend of $0.38 Ami", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNOFRaVHhqRUdYLVdyUDU1bWZOdXE5LUg2aUxTTGxjQXhEejlzR0plMWd1aVR5bGhwS25ZSGI4dTFXeGJVQ0czbjdoSEFjbnd3N3ZxYXl6a0lYWW5tcWNtbGVndGo2VlIwb0RaRU5wTjRPeEQ5cTBCUG9RTmsyWk1PamhOcUNuQmEyOFlHTjRvamdjTmNUbEtFSG00bDV1a0VJeDdHR01QQ0JKbmlBeGwwN21Hbw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T06:08:34+00:00", "published_display": "13 Jul 2026 06:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (NASDAQ: VYNE) declares $0.38/share special dividend tied to merger", "summary": "VYNE Therapeutics has declared an estimated $0.38 per share special cash dividend, totaling $16.5 million, in connection with its proposed merger with Yarrow Bioscience. The dividend is payable to shareholders of record as of July 22, 2026, and its payment is conditional upon the", "url": "https://www.stocktitan.net/sec-filings/VYNE/425-vyne-therapeutics-inc-business-combination-communication-7be9d4fd4eff.html", "source_name": "Stock Titan", "published_at": "2026-07-11T11:11:20", "published_display": "11 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Announces Special Cash Dividend in Connection With Pending Merger With Yarrow Bioscience", "summary": "VYNE Therapeutics announced a special cash dividend of $1.52 per share of common stock in connection with its pending merger with Yarrow Bioscience. The record date for the dividend is set for August 2, 2026, payable on August 5, 2026, contingent upon the closing of the merger. T", "url": "https://www.moomoo.com/news/post/72799569/vyne-therapeutics-announces-special-cash-dividend-in-connection-with-pending", "source_name": "Moomoo", "published_at": "2026-07-11T09:11:44", "published_display": "11 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$16.5 million special payout for VYNE holders hinges on Yarrow merger vote", "summary": "VYNE Therapeutics (Nasdaq: VYNE) has declared a special cash dividend of an estimated $16.5 million, or approximately $0.38 per share, contingent on its proposed merger with Yarrow Bioscience. The payout is set for stockholders and warrant holders of record as of July 22, 2026, w", "url": "https://www.stocktitan.net/news/VYNE/vyne-therapeutics-declares-special-cash-dividend-in-connection-with-knisi53lf56q.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:39:36", "published_display": "10 Jul 2026 23:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (NASDAQ: VYNE) Share Price, VYNE Stock News, VYNE Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE5pTXZsSUl4akdQcFJUaWdJZnQ3SERibFFETjNmZ1pEaE9yYkYtb0pOQjFHQU1aUVVGcTh3Q3N0SjlEYlRLY3V2RDJCaGdQNVhBQXdXSkpn?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T20:22:00+00:00", "published_display": "10 Jul 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPX1dweC1GZVoxajQyZ0lyUTlhS0loTDk5VVBzTkp6NHhlRE14TFdHemU4dms1ZmNVMWlBelhuUG9XV3pHTU5Vem5ncjl2WHEzWEk2MVBmNVJyNzA4ZDRidm1mSElWRmVMekpzb2pPMWxLUEt2OTJpZVVvM1lsa2thRXljSkdraVJwTW9zTmJMMzVETVV2bFZiLU5LVW9lcjd5N3F5TWtoSGtqdVZwXzFpTEFuR2hodTNYb184aDRrUXhsUy15d19fbQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-10T14:35:54+00:00", "published_display": "10 Jul 2026 14:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics declares $16.5M dividend ahead of merger By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPaEpIUVVybjBsLXFPMEpBdDR4Zkp6bEhUcnppQldwaXVjZW5WUGE5TzgxVUQwWElyYzhHV3dKNEZCN2s5OTQtRU9lT0x4WDQ3UWFtLWFPdnNncHFaMWt3dExWOUFCMm9oRGtwZmozRFZUZlVxQl9BV09KUmxIYzU5TzhPU2wySzVmUUJWc1ZpeTFLR05aZ0x3VHJhZFZ5Nmc3RlVTLWVDWmJrdk1WbWtqYVhaY2lmYWk4?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T14:00:30+00:00", "published_display": "10 Jul 2026 14:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Declares Estimated $0.38-Per-Share Special Cash Dividend Ahead of Yarrow Merger", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vyne-therapeutics-declares-estimated-0-123346033.html", "source_name": "MT Newswires", "published_at": "2026-07-10T12:33:46+00:00", "published_display": "10 Jul 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (Nasdaq: VYNE) sets $16.5M special dividend tied to Yarrow merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQWE1IY3AtOHhRNUh0VjRLdkQ1eklaamdyZmg3R1lkQWhzUkZxbHJEX2J0VGs4MU9MX29GejRLMW5WUFZQRDhzdTdGaGpRcnk2cDViRkxMbzA3ZEpaOUdQLUNqZndIQzFuNllaNVB3a3VfZGVIcFV4bVAzX0x6NkVJX1llVVJNY0xESk5nNnl3YnRWdlJhVWlmOWRROF9Sb1VHd1pnb2otWmNTbzZnZE40?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T12:06:58+00:00", "published_display": "10 Jul 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vyne-therapeutics-declares-special-cash-120000100.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T12:00:00+00:00", "published_display": "10 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics declares $16.5M special cash dividend tied to Yarrow merger", "summary": "VYNE Therapeutics announced a special cash dividend of $16.5 million, approximately $0.38 per share, in anticipation of its merger with Yarrow Bioscience. The dividend is payable to stockholders and warrant holders of record as of July 22, 2026, with payment on July 23, 2026. Thi", "url": "https://www.tradingview.com/news/tradingview:e4a70ea5017a0:0-vyne-therapeutics-declares-16-5m-special-cash-dividend-tied-to-yarrow-merger/", "source_name": "TradingView", "published_at": "2026-07-10T12:40:18", "published_display": "10 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Friday's Pre-Market Session", "summary": "This article identifies 12 healthcare stocks that experienced significant movement in Friday's pre-market session. It lists both gainers, such as VYNE Therapeutics and WORK Medical Tech Gr, and losers, including SILO Pharma and Virax Biolabs Group, detailing their percentage chan", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60379932/12-health-care-stocks-moving-friday-s-pre-market-session", "source_name": "Benzinga", "published_at": "2026-07-10T11:40:18", "published_display": "10 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE stock holds its ground. Focus turns to the company profile.", "summary": "This article focuses on VYNE Therapeutics Inc. (VYNE), a clinical-stage biopharmaceutical company specializing in dermatology programs. The company's profile is defined by its pipeline development and capital allocation strategies, which are crucial for investor sentiment. Tradin", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/vyne-stock-holds-its-ground-focus-turns-to-the-company-profile/69713393", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T11:11:16", "published_display": "07 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE - VYNE Therapeutics Inc Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for VYNE Therapeutics Inc (VYNE). It includes key metrics such as market capitalization, income, sales, P/E ratios, insider and institutional ownership, profitability, and stock performance data. The company's targe", "url": "https://finviz.com/stock?t=VYNE&ty=fc", "source_name": "Finviz", "published_at": "2026-07-06T09:40:15", "published_display": "06 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Vyne Therapeutics Inc For: 2 July By Investing.com", "summary": "This article announces the filing of Form 4 for Vyne Therapeutics Inc. on July 2nd. It provides key financial market data including indices, commodities, bonds, and shares, noting performance metrics and top movers. The content also features popular articles and investment challe", "url": "https://ng.investing.com/news/stock-market-news/form-4-vyne-therapeutics-inc-for-2-july-93CH-2585488", "source_name": "Investing.com Nigeria", "published_at": "2026-07-03T21:11:48", "published_display": "03 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (VYNE) CSO reports 2,370-share tax withholding on RSU vesting", "summary": "Stuart Iain, the Chief Scientific Officer of VYNE Therapeutics (VYNE), had 2,370 shares of common stock withheld by the company. This action was taken to cover tax obligations related to the vesting of restricted stock units, with each share valued at $0.6507. Following this non-", "url": "https://www.stocktitan.net/sec-filings/VYNE/form-4-vyne-therapeutics-inc-insider-trading-activity-611ff1167038.html", "source_name": "Stock Titan", "published_at": "2026-07-03T00:10:32", "published_display": "03 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE (VYNE) CFO reports 3,464-share tax withholding on RSU vesting", "summary": "VYNE Therapeutics Inc. CFO Tyler Zeronda reported a routine tax-related share disposition. On June 30, 2026, 3,464 shares of common stock were withheld to cover tax obligations from the vesting of restricted stock units. After this transaction, Zeronda directly held 97,434 shares", "url": "https://www.stocktitan.net/sec-filings/VYNE/form-4-vyne-therapeutics-inc-insider-trading-activity-4af3f7627bfd.html", "source_name": "Stock Titan", "published_at": "2026-07-03T00:10:32", "published_display": "03 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (VYNE) CLO has shares withheld to cover RSU taxes", "summary": "VYNE Therapeutics Inc.'s Chief Legal Officer, Mutya Harsch, had 3,464", "url": "https://www.stocktitan.net/sec-filings/VYNE/form-4-vyne-therapeutics-inc-insider-trading-activity-9aa80951fb51.html", "source_name": "Stock Titan", "published_at": "2026-07-03T00:10:32", "published_display": "03 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE (VYNE) CEO Domzalski has 12,214 shares withheld for RSU taxes", "summary": "VYNE Therapeutics Inc.'s President and CEO, David Domzalski, had 12,214 common shares withheld by the company to satisfy tax obligations related to the vesting of restricted stock units. This transaction, categorized as a tax-related disposition (transaction code F), occurred at ", "url": "https://www.stocktitan.net/sec-filings/VYNE/form-4-vyne-therapeutics-inc-insider-trading-activity-72f23483803f.html", "source_name": "Stock Titan", "published_at": "2026-07-03T00:10:32", "published_display": "03 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of VYNE Therapeutics Inc. \u2013 NASDAQ:VYNE", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for VYNE Therapeutics Inc. (NASDAQ: VYNE) as listed on TradingView. It indicates the stock market where VYNE is traded and notes that the market was closed at the time of data retrieval with no trades. ", "url": "https://www.tradingview.com/symbols/NASDAQ-VYNE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:09:32", "published_display": "27 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of VYNE Therapeutics Inc. \u2013 NASDAQ:VYNE", "summary": "This article provides a financial metric for VYNE Therapeutics Inc. (NASDAQ: VYNE), specifically its \"Price to book forward\" value. It indicates that the NASDAQ market was closed at the time of publication and there were no trades. The content is primarily a data placeholder from", "url": "https://www.tradingview.com/symbols/NASDAQ-VYNE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:10:41", "published_display": "27 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of VYNE Therapeutics Inc. \u2013 NASDAQ:VYNE", "summary": "This article provides financial information for VYNE Therapeutics Inc. (NASDAQ: VYNE), specifically focusing on its forward price-to-earnings ratio. It presents a table showing the period, value, change, and percentage change for this metric, noting that the data is generated by ", "url": "https://www.tradingview.com/symbols/NASDAQ-VYNE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:40:02", "published_display": "27 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of VYNE Therapeutics Inc. \u2013 NASDAQ:VYNE", "summary": "This article provides financial information for VYNE Therapeutics Inc. (NASDAQ: VYNE), focusing on its Enterprise Value to EBITDA (EV/EBITDA) forward metric. The content appears to be a stub or a data point from a financial platform, indicating the metric's value and any changes ", "url": "https://www.tradingview.com/symbols/NASDAQ-VYNE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:11:42", "published_display": "27 Jun 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Inc Actuals & Estimates (NASDAQ:VYNE)", "summary": "This article provides financial actuals and estimates for VYNE Therapeutics Inc. (NASDAQ:VYNE), including its current stock price, market capitalization, volatility, and earnings information. It highlights that VYNE has a market cap of $21.76M, a 6.08% stock volatility, and repor", "url": "https://www.tradingview.com/symbols/NASDAQ-VYNE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:11:42", "published_display": "26 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Inc Actuals & Estimates (BOATS:VYNE)", "summary": "This article provides an overview of VYNE Therapeutics Inc. (BOATS:VYNE) financial actuals and estimates, including its income statement, balance sheet, and cash flow data for both annual and quarterly periods. It also addresses frequently asked questions about the company's stoc", "url": "https://www.tradingview.com/symbols/BOATS-VYNE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:09", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Institutional Confidence", "summary": "Vyne Therapeutics Inc (VYNE) has an institutional shareholding score of 3.00, placing it 193rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 127.19% quarter-over-quarter, reaching 33.26%. James Simons is the largest i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/sentiment", "source_name": "TradingKey", "published_at": "2026-06-23T04:10:08", "published_display": "23 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Valuation: PE, PB & Fair Value Analysis", "summary": "This article analyzes the valuation of Vyne Therapeutics Inc (VYNE), noting its current valuation score of 7.83, ranking it 199 out of 387 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -1.29 and states that relevant data for P/B, P/S, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-22T18:41:52", "published_display": "22 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Vyne Therapeutics Inc (VYNE), detailing its current price momentum score as 3.58, ranking it 358 out of 387 in its industry. It highlights that the stock is trading between resistance at $0.69 and support at $0.61, suggesting suitabil", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/technical", "source_name": "TradingKey", "published_at": "2026-06-22T17:40:03", "published_display": "22 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Stock - Sunday background on a micro-cap dermatology player", "summary": "This article provides a background overview of VYNE Therapeutics, a Nasdaq-listed micro-cap biopharmaceutical company focused on inflammatory skin conditions. It delves into the company's pipeline, management, regulatory reporting, clinical development risks, financial position, ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/vyne-therapeutics-stock-sunday-background-on-a-micro-cap-dermatology/69597975", "source_name": "AD HOC NEWS", "published_at": "2026-06-21T18:11:09", "published_display": "21 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Vyne Therapeutics Inc (VYNE), focusing on its business segments, regional revenue, and profit contribution. It highlights that as of the updated data on April 6, relevant revenue data by business and region have not been disclosed by ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T07:39:10", "published_display": "19 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a detailed historical overview of Vyne Therapeutics Inc (VYNE) dividend payouts and stock split events. It highlights that Vyne Therapeutics has not distributed any dividends over the past five years but has undergone several stock merger splits, notably an 1", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T04:39:10", "published_display": "19 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Vyne Therapeutics Inc (VYNE) currently holds a financial score of 6.55, ranking 241st out of 388 in the Biotechnology & Medical Research industry. Despite robust financial status, the company exhibits low operating efficiency. Its latest quarterly revenue saw a 57.43% year-over-y", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:43", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] VYNE Therapeutics Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOYnJOVkVwekVxcTBqOVNxSXRfbTc4cUE2NzBuSmFoWU9hZDNFc0Rqdl9VcWxWNHpqc3hRcVVBQ25iQk1GLWp2bzlwc0NwVVBOTXIwcm9qQ1JQVXpGX0ZPXzhTNVkwclNXQ0wtbGpLOF9kc2NGeHcwMUpQWHAzR3BRZGE4NWVjR3NqcmRkbjh3TzVWUGpBN2RMYUpYTDFUWVRHMW1r?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhang Xiaofan discloses 1.87M shares (5.6%) in VYNE Therapeutics (VYNE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQeTdnZWlVMWpHWUtTcHpuaEItYk9rSE9RdEl6ZE5Wb2lsbU1GQk5QS0J5UXpuM2hXc3MxRkY2NlViVE8yamhfdXJFbE1kVENQV3UzemFxblFOSVFYZnAtVFc1WF9iWmMxQ3NyT2dQb3cxMHB6TnNyX0lfMnQ1VndHUWswNVM0VUp6NDFXQkhxTkJEeGJMZEJPNDN1UERQZXZQNGxFRktES1NzLV9KMU1RRnJxQkR0UHROb2dGNlF2a1Blb01nbkpN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vyne Therapeutics stock soars after merger with Yarrow Bioscience", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOV1N5WkRRZGVDSUxFU0JGVlpEcWpKRXpxd1p5YTVsVmlodkc4RXlZckZMYlBkNndJeC1zRVV5OXZUbHhxd1RxY2RoUUJzSlU3SGlkeFJRRVBPTG82LWpTam9OWDZqbW1KdnU2RXhUZmw3R19UY2RCcjk1UGdVcEJFU21VQnpaY1VDWk54VGpNS3Vfaml3WGJzaU1IZERDV0VzUG5jN3BBX3RrcmJTbV9hOFBrMWVUTGk2bFBPS0IzZk5xRkZNbFE?oc=5", "source_name": "Investing.com", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics (VYNE) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1XZ0NyWm5ZeDVMSnBOZUdXLS1nOWZkUjg4MEwySjA1THhDbDl1djBCUkhnWHVsY0U1QUp5SHFlS1RfUGlYSWFJV25uSVVnUQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPOW5ST25MYVhMT3dvWXdwSWFZVEE4VEw0b251TmxrZ21GaW5YU2laRkJTeVZvQjRMUzZaZjJxMXhnUjZUaDBZNVI2VmdtT0p6Mnp1QnFGNFM4R05jYm5vbWxGbzhYQWNnRm1oeHkzM2VERzdhS2lBZVVWOWNReUF0dkV3Zk05RndNbEUzUGNVbVl2Yld0aE00U1p2OGRTNEg0b0Z2aWVITkpKbFo4cGJrcEJtSGRSQ1A2RW5ONWpPT2FLN3pMSW1NNWRuZW9zX1FnalE5X0VveERGYXZtTGJiNTJRSkJDQdIB6wFBVV95cUxQVlBWX0drRThwX2Y4b0NsYS0taUxTd2Fzd0VyN2hRRnNCbGtfR0ZPd0N2TDY1NXRsUUJZc2xYclcyLVJYY1dMR1hnRUM5TUQ1VEZRb3A4bkdmeGREMnlPeTN5TFg3aGhnNW92WURFY2F3ejNLRTM2UEhoR1IxT3NJZ1FyN1UwbzNIM1VNVDVQc3dHX09UTEtGOERwRVUtLXd1d0pkbV9SeFEwdTM2M29lc0htYnUxWmh5cExVWUtuZzBFZnJ5VU9lLVVWQVpUWEY3bXpvc01jLVBxZk11Z2FzbE5tcjlnYXNYSksw?oc=5", "source_name": "simplywall.st", "published_at": "2025-06-27T07:00:00+00:00", "published_display": "27 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics (VYNE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE80OFZ6a3VhQTNHQ013Rl9UbmoyVGQyWDdaVUxVQlQxbHNCcmZTcTlXMHNQVVVpVnJyclgzOTQybFkyUnBJbmNWUmU1dkg4VmVTREVn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:41:49+00:00", "published_display": "25 Apr 2025 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Inc. (VYNE) Stock Price, Chart, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTFAwQVlkcmtvMkpOcDFZMkdFTDM3Yk5pVU54WU9qZDk5M0xIZjFaLW1JWk9WUUpyd0RuSnNfcU44bkJiN01TZ3ZZZ0JqMHlIUFE?oc=5", "source_name": "Securities.io", "published_at": "2024-11-01T00:23:53+00:00", "published_display": "01 Nov 2024 00:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "VYNE Therapeutics Inc. (VYNE) reports 13.8% stake by Zhang Xiaofan", "summary": "Zhang Xiaofan has reported a 13.8% beneficial ownership stake in VYNE Therapeutics Inc., holding 4,595,118 shares of common stock. This SCHEDULE 13G/A filing indicates that Zhang Xiaofan has sole voting and dispositive power over these shares. The filing lists Zhang Xiaofan's bus", "url": "https://www.stocktitan.net/sec-filings/VYNE/schedule-13g-a-vyne-therapeutics-inc-amended-passive-investment-discl-eeb0bd4053fe.html", "source_name": "Stock Titan", "published_at": "2026-07-14T13:39:35", "published_display": "14 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (NASDAQ: VYNE) shares Yarrow transaction deck", "summary": "VYNE Therapeutics Inc. (NASDAQ: VYNE) reported that Yarrow Bioscience, Inc. has published an investor presentation for investor relations, dated July 14, 2026. This presentation has been made available on VYNE's investor website and filed as Exhibit 99.1. It is clarified that thi", "url": "https://www.stocktitan.net/sec-filings/VYNE/425-vyne-therapeutics-inc-business-combination-communication-c60b38a0f1da.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:39:35", "published_display": "14 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (NASDAQ: VYNE) outlines Yarrow merger, dividend terms", "summary": "VYNE Therapeutics has detailed its proposed reverse merger with Yarrow Bioscience, where the combined company will trade as YARW on Nasdaq around July 24, 2026. Yarrow, founded in 2025, is developing YB-101, an anti-TSHR antibody for Graves\u2019 disease and thyroid eye disease, with ", "url": "https://www.stocktitan.net/sec-filings/VYNE/8-k-vyne-therapeutics-inc-reports-material-event-d25f763da3f2.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:39:35", "published_display": "14 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (VYNE) Announces Special Dividend of $0.38 Ami", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNOFRaVHhqRUdYLVdyUDU1bWZOdXE5LUg2aUxTTGxjQXhEejlzR0plMWd1aVR5bGhwS25ZSGI4dTFXeGJVQ0czbjdoSEFjbnd3N3ZxYXl6a0lYWW5tcWNtbGVndGo2VlIwb0RaRU5wTjRPeEQ5cTBCUG9RTmsyWk1PamhOcUNuQmEyOFlHTjRvamdjTmNUbEtFSG00bDV1a0VJeDdHR01QQ0JKbmlBeGwwN21Hbw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T06:08:34+00:00", "published_display": "13 Jul 2026 06:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (NASDAQ: VYNE) declares $0.38/share special dividend tied to merger", "summary": "VYNE Therapeutics has declared an estimated $0.38 per share special cash dividend, totaling $16.5 million, in connection with its proposed merger with Yarrow Bioscience. The dividend is payable to shareholders of record as of July 22, 2026, and its payment is conditional upon the", "url": "https://www.stocktitan.net/sec-filings/VYNE/425-vyne-therapeutics-inc-business-combination-communication-7be9d4fd4eff.html", "source_name": "Stock Titan", "published_at": "2026-07-11T11:11:20", "published_display": "11 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Announces Special Cash Dividend in Connection With Pending Merger With Yarrow Bioscience", "summary": "VYNE Therapeutics announced a special cash dividend of $1.52 per share of common stock in connection with its pending merger with Yarrow Bioscience. The record date for the dividend is set for August 2, 2026, payable on August 5, 2026, contingent upon the closing of the merger. T", "url": "https://www.moomoo.com/news/post/72799569/vyne-therapeutics-announces-special-cash-dividend-in-connection-with-pending", "source_name": "Moomoo", "published_at": "2026-07-11T09:11:44", "published_display": "11 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$16.5 million special payout for VYNE holders hinges on Yarrow merger vote", "summary": "VYNE Therapeutics (Nasdaq: VYNE) has declared a special cash dividend of an estimated $16.5 million, or approximately $0.38 per share, contingent on its proposed merger with Yarrow Bioscience. The payout is set for stockholders and warrant holders of record as of July 22, 2026, w", "url": "https://www.stocktitan.net/news/VYNE/vyne-therapeutics-declares-special-cash-dividend-in-connection-with-knisi53lf56q.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:39:36", "published_display": "10 Jul 2026 23:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (NASDAQ: VYNE) Share Price, VYNE Stock News, VYNE Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE5pTXZsSUl4akdQcFJUaWdJZnQ3SERibFFETjNmZ1pEaE9yYkYtb0pOQjFHQU1aUVVGcTh3Q3N0SjlEYlRLY3V2RDJCaGdQNVhBQXdXSkpn?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T20:22:00+00:00", "published_display": "10 Jul 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPX1dweC1GZVoxajQyZ0lyUTlhS0loTDk5VVBzTkp6NHhlRE14TFdHemU4dms1ZmNVMWlBelhuUG9XV3pHTU5Vem5ncjl2WHEzWEk2MVBmNVJyNzA4ZDRidm1mSElWRmVMekpzb2pPMWxLUEt2OTJpZVVvM1lsa2thRXljSkdraVJwTW9zTmJMMzVETVV2bFZiLU5LVW9lcjd5N3F5TWtoSGtqdVZwXzFpTEFuR2hodTNYb184aDRrUXhsUy15d19fbQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-10T14:35:54+00:00", "published_display": "10 Jul 2026 14:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics declares $16.5M dividend ahead of merger By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPaEpIUVVybjBsLXFPMEpBdDR4Zkp6bEhUcnppQldwaXVjZW5WUGE5TzgxVUQwWElyYzhHV3dKNEZCN2s5OTQtRU9lT0x4WDQ3UWFtLWFPdnNncHFaMWt3dExWOUFCMm9oRGtwZmozRFZUZlVxQl9BV09KUmxIYzU5TzhPU2wySzVmUUJWc1ZpeTFLR05aZ0x3VHJhZFZ5Nmc3RlVTLWVDWmJrdk1WbWtqYVhaY2lmYWk4?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T14:00:30+00:00", "published_display": "10 Jul 2026 14:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Declares Estimated $0.38-Per-Share Special Cash Dividend Ahead of Yarrow Merger", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vyne-therapeutics-declares-estimated-0-123346033.html", "source_name": "MT Newswires", "published_at": "2026-07-10T12:33:46+00:00", "published_display": "10 Jul 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (Nasdaq: VYNE) sets $16.5M special dividend tied to Yarrow merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQWE1IY3AtOHhRNUh0VjRLdkQ1eklaamdyZmg3R1lkQWhzUkZxbHJEX2J0VGs4MU9MX29GejRLMW5WUFZQRDhzdTdGaGpRcnk2cDViRkxMbzA3ZEpaOUdQLUNqZndIQzFuNllaNVB3a3VfZGVIcFV4bVAzX0x6NkVJX1llVVJNY0xESk5nNnl3YnRWdlJhVWlmOWRROF9Sb1VHd1pnb2otWmNTbzZnZE40?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T12:06:58+00:00", "published_display": "10 Jul 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vyne-therapeutics-declares-special-cash-120000100.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T12:00:00+00:00", "published_display": "10 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics declares $16.5M special cash dividend tied to Yarrow merger", "summary": "VYNE Therapeutics announced a special cash dividend of $16.5 million, approximately $0.38 per share, in anticipation of its merger with Yarrow Bioscience. The dividend is payable to stockholders and warrant holders of record as of July 22, 2026, with payment on July 23, 2026. Thi", "url": "https://www.tradingview.com/news/tradingview:e4a70ea5017a0:0-vyne-therapeutics-declares-16-5m-special-cash-dividend-tied-to-yarrow-merger/", "source_name": "TradingView", "published_at": "2026-07-10T12:40:18", "published_display": "10 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Friday's Pre-Market Session", "summary": "This article identifies 12 healthcare stocks that experienced significant movement in Friday's pre-market session. It lists both gainers, such as VYNE Therapeutics and WORK Medical Tech Gr, and losers, including SILO Pharma and Virax Biolabs Group, detailing their percentage chan", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60379932/12-health-care-stocks-moving-friday-s-pre-market-session", "source_name": "Benzinga", "published_at": "2026-07-10T11:40:18", "published_display": "10 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE stock holds its ground. Focus turns to the company profile.", "summary": "This article focuses on VYNE Therapeutics Inc. (VYNE), a clinical-stage biopharmaceutical company specializing in dermatology programs. The company's profile is defined by its pipeline development and capital allocation strategies, which are crucial for investor sentiment. Tradin", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/vyne-stock-holds-its-ground-focus-turns-to-the-company-profile/69713393", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T11:11:16", "published_display": "07 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE - VYNE Therapeutics Inc Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for VYNE Therapeutics Inc (VYNE). It includes key metrics such as market capitalization, income, sales, P/E ratios, insider and institutional ownership, profitability, and stock performance data. The company's targe", "url": "https://finviz.com/stock?t=VYNE&ty=fc", "source_name": "Finviz", "published_at": "2026-07-06T09:40:15", "published_display": "06 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Vyne Therapeutics Inc For: 2 July By Investing.com", "summary": "This article announces the filing of Form 4 for Vyne Therapeutics Inc. on July 2nd. It provides key financial market data including indices, commodities, bonds, and shares, noting performance metrics and top movers. The content also features popular articles and investment challe", "url": "https://ng.investing.com/news/stock-market-news/form-4-vyne-therapeutics-inc-for-2-july-93CH-2585488", "source_name": "Investing.com Nigeria", "published_at": "2026-07-03T21:11:48", "published_display": "03 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (VYNE) CSO reports 2,370-share tax withholding on RSU vesting", "summary": "Stuart Iain, the Chief Scientific Officer of VYNE Therapeutics (VYNE), had 2,370 shares of common stock withheld by the company. This action was taken to cover tax obligations related to the vesting of restricted stock units, with each share valued at $0.6507. Following this non-", "url": "https://www.stocktitan.net/sec-filings/VYNE/form-4-vyne-therapeutics-inc-insider-trading-activity-611ff1167038.html", "source_name": "Stock Titan", "published_at": "2026-07-03T00:10:32", "published_display": "03 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE (VYNE) CFO reports 3,464-share tax withholding on RSU vesting", "summary": "VYNE Therapeutics Inc. CFO Tyler Zeronda reported a routine tax-related share disposition. On June 30, 2026, 3,464 shares of common stock were withheld to cover tax obligations from the vesting of restricted stock units. After this transaction, Zeronda directly held 97,434 shares", "url": "https://www.stocktitan.net/sec-filings/VYNE/form-4-vyne-therapeutics-inc-insider-trading-activity-4af3f7627bfd.html", "source_name": "Stock Titan", "published_at": "2026-07-03T00:10:32", "published_display": "03 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics (VYNE) CLO has shares withheld to cover RSU taxes", "summary": "VYNE Therapeutics Inc.'s Chief Legal Officer, Mutya Harsch, had 3,464", "url": "https://www.stocktitan.net/sec-filings/VYNE/form-4-vyne-therapeutics-inc-insider-trading-activity-9aa80951fb51.html", "source_name": "Stock Titan", "published_at": "2026-07-03T00:10:32", "published_display": "03 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE (VYNE) CEO Domzalski has 12,214 shares withheld for RSU taxes", "summary": "VYNE Therapeutics Inc.'s President and CEO, David Domzalski, had 12,214 common shares withheld by the company to satisfy tax obligations related to the vesting of restricted stock units. This transaction, categorized as a tax-related disposition (transaction code F), occurred at ", "url": "https://www.stocktitan.net/sec-filings/VYNE/form-4-vyne-therapeutics-inc-insider-trading-activity-72f23483803f.html", "source_name": "Stock Titan", "published_at": "2026-07-03T00:10:32", "published_display": "03 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of VYNE Therapeutics Inc. \u2013 NASDAQ:VYNE", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for VYNE Therapeutics Inc. (NASDAQ: VYNE) as listed on TradingView. It indicates the stock market where VYNE is traded and notes that the market was closed at the time of data retrieval with no trades. ", "url": "https://www.tradingview.com/symbols/NASDAQ-VYNE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:09:32", "published_display": "27 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of VYNE Therapeutics Inc. \u2013 NASDAQ:VYNE", "summary": "This article provides a financial metric for VYNE Therapeutics Inc. (NASDAQ: VYNE), specifically its \"Price to book forward\" value. It indicates that the NASDAQ market was closed at the time of publication and there were no trades. The content is primarily a data placeholder from", "url": "https://www.tradingview.com/symbols/NASDAQ-VYNE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:10:41", "published_display": "27 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of VYNE Therapeutics Inc. \u2013 NASDAQ:VYNE", "summary": "This article provides financial information for VYNE Therapeutics Inc. (NASDAQ: VYNE), specifically focusing on its forward price-to-earnings ratio. It presents a table showing the period, value, change, and percentage change for this metric, noting that the data is generated by ", "url": "https://www.tradingview.com/symbols/NASDAQ-VYNE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:40:02", "published_display": "27 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of VYNE Therapeutics Inc. \u2013 NASDAQ:VYNE", "summary": "This article provides financial information for VYNE Therapeutics Inc. (NASDAQ: VYNE), focusing on its Enterprise Value to EBITDA (EV/EBITDA) forward metric. The content appears to be a stub or a data point from a financial platform, indicating the metric's value and any changes ", "url": "https://www.tradingview.com/symbols/NASDAQ-VYNE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:11:42", "published_display": "27 Jun 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Inc Actuals & Estimates (NASDAQ:VYNE)", "summary": "This article provides financial actuals and estimates for VYNE Therapeutics Inc. (NASDAQ:VYNE), including its current stock price, market capitalization, volatility, and earnings information. It highlights that VYNE has a market cap of $21.76M, a 6.08% stock volatility, and repor", "url": "https://www.tradingview.com/symbols/NASDAQ-VYNE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:11:42", "published_display": "26 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Inc Actuals & Estimates (BOATS:VYNE)", "summary": "This article provides an overview of VYNE Therapeutics Inc. (BOATS:VYNE) financial actuals and estimates, including its income statement, balance sheet, and cash flow data for both annual and quarterly periods. It also addresses frequently asked questions about the company's stoc", "url": "https://www.tradingview.com/symbols/BOATS-VYNE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:09", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Institutional Confidence", "summary": "Vyne Therapeutics Inc (VYNE) has an institutional shareholding score of 3.00, placing it 193rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 127.19% quarter-over-quarter, reaching 33.26%. James Simons is the largest i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/sentiment", "source_name": "TradingKey", "published_at": "2026-06-23T04:10:08", "published_display": "23 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Valuation: PE, PB & Fair Value Analysis", "summary": "This article analyzes the valuation of Vyne Therapeutics Inc (VYNE), noting its current valuation score of 7.83, ranking it 199 out of 387 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -1.29 and states that relevant data for P/B, P/S, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-22T18:41:52", "published_display": "22 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Vyne Therapeutics Inc (VYNE), detailing its current price momentum score as 3.58, ranking it 358 out of 387 in its industry. It highlights that the stock is trading between resistance at $0.69 and support at $0.61, suggesting suitabil", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/technical", "source_name": "TradingKey", "published_at": "2026-06-22T17:40:03", "published_display": "22 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Stock - Sunday background on a micro-cap dermatology player", "summary": "This article provides a background overview of VYNE Therapeutics, a Nasdaq-listed micro-cap biopharmaceutical company focused on inflammatory skin conditions. It delves into the company's pipeline, management, regulatory reporting, clinical development risks, financial position, ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/vyne-therapeutics-stock-sunday-background-on-a-micro-cap-dermatology/69597975", "source_name": "AD HOC NEWS", "published_at": "2026-06-21T18:11:09", "published_display": "21 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Vyne Therapeutics Inc (VYNE), focusing on its business segments, regional revenue, and profit contribution. It highlights that as of the updated data on April 6, relevant revenue data by business and region have not been disclosed by ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T07:39:10", "published_display": "19 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a detailed historical overview of Vyne Therapeutics Inc (VYNE) dividend payouts and stock split events. It highlights that Vyne Therapeutics has not distributed any dividends over the past five years but has undergone several stock merger splits, notably an 1", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T04:39:10", "published_display": "19 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics Inc (VYNE) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Vyne Therapeutics Inc (VYNE) currently holds a financial score of 6.55, ranking 241st out of 388 in the Biotechnology & Medical Research industry. Despite robust financial status, the company exhibits low operating efficiency. Its latest quarterly revenue saw a 57.43% year-over-y", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vyne/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:43", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] VYNE Therapeutics Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOYnJOVkVwekVxcTBqOVNxSXRfbTc4cUE2NzBuSmFoWU9hZDNFc0Rqdl9VcWxWNHpqc3hRcVVBQ25iQk1GLWp2bzlwc0NwVVBOTXIwcm9qQ1JQVXpGX0ZPXzhTNVkwclNXQ0wtbGpLOF9kc2NGeHcwMUpQWHAzR3BRZGE4NWVjR3NqcmRkbjh3TzVWUGpBN2RMYUpYTDFUWVRHMW1r?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhang Xiaofan discloses 1.87M shares (5.6%) in VYNE Therapeutics (VYNE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQeTdnZWlVMWpHWUtTcHpuaEItYk9rSE9RdEl6ZE5Wb2lsbU1GQk5QS0J5UXpuM2hXc3MxRkY2NlViVE8yamhfdXJFbE1kVENQV3UzemFxblFOSVFYZnAtVFc1WF9iWmMxQ3NyT2dQb3cxMHB6TnNyX0lfMnQ1VndHUWswNVM0VUp6NDFXQkhxTkJEeGJMZEJPNDN1UERQZXZQNGxFRktES1NzLV9KMU1RRnJxQkR0UHROb2dGNlF2a1Blb01nbkpN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics stock soars after merger with Yarrow Bioscience", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOV1N5WkRRZGVDSUxFU0JGVlpEcWpKRXpxd1p5YTVsVmlodkc4RXlZckZMYlBkNndJeC1zRVV5OXZUbHhxd1RxY2RoUUJzSlU3SGlkeFJRRVBPTG82LWpTam9OWDZqbW1KdnU2RXhUZmw3R19UY2RCcjk1UGdVcEJFU21VQnpaY1VDWk54VGpNS3Vfaml3WGJzaU1IZERDV0VzUG5jN3BBX3RrcmJTbV9hOFBrMWVUTGk2bFBPS0IzZk5xRkZNbFE?oc=5", "source_name": "Investing.com", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics (VYNE) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1XZ0NyWm5ZeDVMSnBOZUdXLS1nOWZkUjg4MEwySjA1THhDbDl1djBCUkhnWHVsY0U1QUp5SHFlS1RfUGlYSWFJV25uSVVnUQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-06-27T07:00:00+00:00", "published_display": "27 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics (VYNE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE80OFZ6a3VhQTNHQ013Rl9UbmoyVGQyWDdaVUxVQlQxbHNCcmZTcTlXMHNQVVVpVnJyclgzOTQybFkyUnBJbmNWUmU1dkg4VmVTREVn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:41:49+00:00", "published_display": "25 Apr 2025 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VYNE Therapeutics Inc. (VYNE) Stock Price, Chart, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTFAwQVlkcmtvMkpOcDFZMkdFTDM3Yk5pVU54WU9qZDk5M0xIZjFaLW1JWk9WUUpyd0RuSnNfcU44bkJiN01TZ3ZZZ0JqMHlIUFE?oc=5", "source_name": "Securities.io", "published_at": "2024-11-01T00:23:53+00:00", "published_display": "01 Nov 2024 00:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 84, "total_relevant": 50, "sentiment_summary": {"positive": 6, "negative": 3, "neutral": 41, "score": 51, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 74, "events": [{"event": "general", "label": "Market update", "weight": 10.45, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 5.5, "count": 10}, {"event": "capital_return", "label": "Capital return", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 6, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 0.64, "latest_week": "2026-07-10", "one_week_move": -6.2, "four_week_move": -1.7, "twelve_week_move": 4.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.303371, "market_dynamics_buy_signal": false, "relative_strength": 1.509921, "fair_value_gap": -65.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.963, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.2% over one week, -1.7% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 6}, {"label": "Market source", "count": 5}, {"label": "simplywall.st", "count": 3}, {"label": "AD HOC NEWS", "count": 2}, {"label": "GuruFocus", "count": 1}, {"label": "Moomoo", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 19}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 10}, {"label": "Capital return", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.2% over one week, -1.7% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "VYNE Therapeutics Inc. (VYNE) reports 13.8% stake by Zhang Xiaofan"}], "updated_at": "2026-07-16T08:06:38.879578+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}